Overview
- Pfizer completed the purchase of Metsera for $65.60 per share in cash plus up to $20.65 per share in contingent value rights, and Metsera’s stock was delisted from Nasdaq today.
- The outcome capped a months‑long contest with Novo Nordisk, which withdrew after the FTC warned Metsera that Novo’s proposed two‑step structure could pose antitrust risks.
- Pfizer gains late‑stage obesity assets including MET‑097i, a weekly and monthly injectable GLP‑1 set to enter Phase 3, MET‑233i, a monthly amylin analog in Phase 1, and an oral GLP‑1 in early trials.
- CEO Albert Bourla said the deal underpins Pfizer’s push to compete in obesity and that first products could reach the market in 2028 if development and regulatory milestones are met.
- Pfizer said the transaction will be dilutive through 2030 as it invests in the pipeline, with an updated financial outlook to come alongside 2026 guidance.